A detailed history of Bank Of America Corp transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Bank Of America Corp holds 246,961 shares of ASND stock, worth $29.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
246,961
Previous 264,445 6.61%
Holding current value
$29.4 Million
Previous $40 Million 15.75%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$121.07 - $153.67 $2.12 Million - $2.69 Million
-17,484 Reduced 6.61%
246,961 $33.7 Million
Q1 2024

May 15, 2024

BUY
$123.45 - $159.4 $13.9 Million - $17.9 Million
112,607 Added 74.16%
264,445 $40 Million
Q4 2023

Feb 14, 2024

SELL
$86.1 - $127.36 $10.2 Million - $15.1 Million
-118,853 Reduced 43.91%
151,838 $19.1 Million
Q2 2023

Aug 14, 2023

BUY
$69.96 - $97.84 $17.5 Million - $24.5 Million
250,700 Added 1254.06%
270,691 $24.2 Million
Q1 2023

May 12, 2023

SELL
$104.9 - $126.78 $1.03 Million - $1.24 Million
-9,817 Reduced 32.93%
19,991 $2.14 Million
Q4 2022

Feb 10, 2023

BUY
$99.42 - $131.97 $913,868 - $1.21 Million
9,192 Added 44.59%
29,808 $3.64 Million
Q3 2022

Nov 14, 2022

BUY
$84.03 - $110.23 $221,503 - $290,566
2,636 Added 14.66%
20,616 $2.13 Million
Q2 2022

Aug 12, 2022

BUY
$78.08 - $117.61 $174,664 - $263,093
2,237 Added 14.21%
17,980 $1.67 Million
Q1 2022

May 16, 2022

BUY
$102.18 - $135.75 $515,293 - $684,587
5,043 Added 47.13%
15,743 $1.85 Million
Q4 2021

Feb 08, 2022

SELL
$127.1 - $169.66 $555,172 - $741,074
-4,368 Reduced 28.99%
10,700 $1.44 Million
Q3 2021

Nov 15, 2021

SELL
$112.67 - $176.92 $6,084 - $9,553
-54 Reduced 0.36%
15,068 $2.4 Million
Q2 2021

Sep 13, 2021

BUY
$121.62 - $145.29 $1.84 Million - $2.2 Million
15,122 New
15,122 $1.99 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $6.64B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.